From Variant to Biomarker in NSCLC Immunotherapy Resistance: Multiomics Evidence Chains and Accountable AI Integration

Yiqing Jiang, Na Wang, Qin Zeng, Jun Liu, Xiaoqin Liu, Guili Cao · 2026

Read From Variant to Biomarker in NSCLC Immunotherapy Resistance: Multiomics Evidence Chains and Accountable AI Integration by Yiqing Jiang, Na Wang, Qin Zeng, Jun Liu, Xiaoqin Liu, Guili Cao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13191777.txt.

Description

Immunotherapy has changed lung cancer care, but many tumours resist it from the start or learn to resist, and the two routine markers explain only part of that story. Yiqing Jiang and co-authors argue that resistance is a many-sided state. It is shaped by how visible the tumour is to the immune system and how well it presents its antigens. Interferon signalling, the layout of immune cells, suppressive neighbourhoods, and metabolic limits on killer cells all play a part.

Their proposal is to build evidence chains. Start from a genetic variant, then follow its effects across the other omics layers — transcripts, epigenetics, proteins, metabolites — plus spatial and imaging data. The chain ends at a trustworthy biomarker. Artificial intelligence can help assemble those chains, the authors argue, provided it stays accountable. The article lays out the framework rather than reporting a single experiment.

Catalog record

CREATORYiqing Jiang, Na Wang, Qin Zeng, Jun Liu, Xiaoqin Liu, Guili Cao
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE29 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13191777

Browse the full library · About the Tower of Babel